{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:29:02Z","timestamp":1777109342670,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In Norway, the breast cancer incidence increased by 50% in the 1990s, during a period with initiation of mammography screening as well as a fourfold increase in use of menopausal hormone therapy (<jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content>). After 2002, the <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> use has dropped substantially; however, the breast cancer incidence has declined only marginally. How much mammography screening contributed to the breast cancer incidence increase in the 1990s compared with <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> use and specifically different types of <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> use, has thus been discussed. Whether <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> affects the incidence of subtypes of breast cancer differently has also been questioned. We have linked individual data from several national registries from 2004 to 2009 on 449,717 women aged 50\u201365\u00a0years. 4597 cases of invasive cancer and 681 cases of ductal carcinoma in\u00a0situ (<jats:styled-content style=\"fixed-case\">DCIS<\/jats:styled-content>) were included in the analysis. We used Cox regression to estimate hazard ratio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) as a measure of the relative risk of breast cancer associated with use of <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content>. The <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>s associated with prescriptions of <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> for more than 1\u00a0year were 2.06 (1.90\u20132.24) for estrogen and progesterone combinations, 1.03 (0.85\u20131.25) for systemic estrogens, and 1.23 (1.01\u20131.51) for tibolone. Invasive lobular carcinoma was more strongly associated with use of estrogen and progesterone combinations, <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a03.10 (2.51\u20133.81), than nonlobular carcinoma, <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a01.94 (1.78\u20132.12). The corresponding value for <jats:styled-content style=\"fixed-case\">DCIS<\/jats:styled-content> was 1.61 (1.28\u20132.02). We estimated the population attributable fraction to 8.2%, corresponding to 90 breast cancer cases in 2006 indicating that <jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content> use still caused a major number of breast cancer cases.<\/jats:p>","DOI":"10.1002\/cam4.474","type":"journal-article","created":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T06:09:32Z","timestamp":1432102172000},"page":"1303-1308","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register\u2010based cohort study"],"prefix":"10.1002","volume":"4","author":[{"given":"P\u00e5l","family":"Suhrke","sequence":"first","affiliation":[{"name":"Department of Pathology Oslo University Hospital PO Box 4950 Nydalen N\u20100424 Oslo Norway"},{"name":"Department of Pathology Vestfold Hospital Trust PO Box 2168 N\u20103103 T\u00f8nsberg Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per\u2010Henrik","family":"Zahl","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health PO Box 4404 Nydalen N\u20100403 Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2587"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21742"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20389"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)08233-0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.4.328"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.4.485"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14596-5"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61255-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26280"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38044.666157.63"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-007-9137-y"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e299"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.6.734"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10984"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023634907723"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2960-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2402-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.9.1036"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.474","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T13:52:45Z","timestamp":1696600365000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1002\/cam4.474"],"URL":"https:\/\/doi.org\/10.1002\/cam4.474","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,20]]},"assertion":[{"value":"2015-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}